BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9342006)

  • 1. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients.
    Stephens RW; Pedersen AN; Nielsen HJ; Hamers MJ; Høyer-Hansen G; Rønne E; Dybkjaer E; Danø K; Brünner N
    Clin Chem; 1997 Oct; 43(10):1868-76. PubMed ID: 9342006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
    Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
    Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
    Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
    Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
    Slot O; Brünner N; Locht H; Oxholm P; Stephens RW
    Ann Rheum Dis; 1999 Aug; 58(8):488-92. PubMed ID: 10419867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
    Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
    Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
    Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
    Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
    Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
    Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.
    Jensen MK; Riisbro R; de Nully Brown P; Brünner N; Hasselbalch HC
    Eur J Haematol; 2002 Jul; 69(1):43-9. PubMed ID: 12270061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
    Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
    J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.
    Riisbro R; Christensen IJ; Nielsen HJ; Brünner N; Nilbert M; Fernebro E
    Int J Biol Markers; 2005; 20(2):93-102. PubMed ID: 16011039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
    De Witte H; Sweep F; Brünner N; Heuvel J; Beex L; Grebenschikov N; Benraad T
    Int J Cancer; 1998 Jul; 77(2):236-42. PubMed ID: 9650559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New ELISA for quantitation of human urokinase receptor (CD87) in cancer.
    Kotzsch M; Luther T; Harbeck N; Ockert D; Lutz V; Noack F; Grossmann D; Albrecht S; Kramer MD; Lossnitzer A; Grosser M; Schmitt M; Magdolen V
    Int J Oncol; 2000 Oct; 17(4):827-34. PubMed ID: 10995898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients.
    Fernebro E; Madsen RR; Fernö M; Brünner N; Bendahl P; Christensen IJ; Johnson A; Nilbert M
    Eur J Cancer; 2001 Mar; 37(4):486-91. PubMed ID: 11267858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
    Holst-Hansen C; Hamers MJ; Johannessen BE; Brünner N; Stephens RW
    Br J Cancer; 1999 Sep; 81(2):203-11. PubMed ID: 10496343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of soluble urokinase receptor by immunoradiometric assay and its application in tumor patients.
    Gao W; Wang Z; Bai X; Xi X; Ruan C
    Thromb Res; 2001 Apr; 102(1):25-31. PubMed ID: 11323011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
    Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
    Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients.
    Pappot H; Høyer-Hansen G; Rønne E; Hansen HH; Brünner N; Danø K; Grøndahl-Hansen J
    Eur J Cancer; 1997 May; 33(6):867-72. PubMed ID: 9291807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.